₹68 per tablet.The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use, Cipla said."To ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases," the company said.
Ciplenza has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). "As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir.